

287 Panic Disorder

REFERENCES

1. Katerndahl DA, Realini JP: Use of health care services by persons with panic disorder. *Psychiatr Serv* 48: 1027, 1997.
2. Simpson RJ, Kazmierczak T, Power KG, et al: Controlled comparison of the characteristics of patients with panic disorder. *Br J Gen Pract* 44: 352, 1994.
3. Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry* 51: 8, 1994.
4. Weissman MM, Bland RC, Canino GJ, et al: The cross-national epidemiology of panic disorder. *Arch Gen Psychiatry* 54: 305, 1997.
5. American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision*. Washington, DC, American Psychiatric Association, 2000.
6. Cohen LS, Sichel DA, Dimmock JA, et al: Postpartum course in women with preexisting panic disorder. *J Clin Psychiatry* 55: 289, 1994.
7. Paradis CM, Friedman S: Sleep paralysis in African Americans with panic disorder. *Transcult Psychiatry* 42: 692, 2005.
8. Hinton DE, Hinton L, Tran M, et al: Orthostatic panic attacks among Vietnamese refugees. *Transcult Psychiatry* 44: 515, 2007.
9. Liebowitz MR, Salman E, Justino CM, et al: Ataque de nervios and panic disorder. *Am J Psychiatry* 151: 871, 1994.
10. Knowles JA, Weissman MM: Panic disorder and agoraphobia, in Oldham JM, Riba MB (eds): *American Psychiatric Press Review of Psychiatry*, vol 14. Washington, DC, American Psychiatric Press, 1995, p. 383.
11. Perna G, Caldirola D, Arancio C, et al: Panic attacks: a twin study. *Psychiatr Res* 15: 69, 1997.
12. Bourin M, Baker GB, Bradwejn J: Neurobiology of panic disorder. *J Psychosom Res* 44: 163, 1998.
13. Klein DF, Gorman JM: A model of panic and agoraphobic development. *Acta Psychiatr Scand* 335: 87, 1987.
14. Bradwejn J, Koszycki D: Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. *Am J Psychiatry* 15: 261, 1994.
15. Zun LS: Panic disorder: diagnosis and treatment in emergency medicine. *Ann Emerg Med* 30: 92, 1997.
16. Zaubler TS, Katon W: Panic disorder in the medical setting. *J Psychosom Res* 44: 25, 1998.
17. Ballenger JC: Treatment of panic disorder in the general medical setting. *J Psychosom Res* 44: 5, 1998.
18. Katschnig H, Amering M, Stolk JM, et al: Predictors of quality of life in a long-term follow-up study of panic disorder patients after a clinical drug trial. *Psychopharmacol Bull* 32: 149, 1996.
19. Johnson J, Weissman MM, Klerman GL: Panic disorder, comorbidity, and suicide attempts. *Arch Gen Psychiatry* 47: 805, 1990.
20. Swinson RP, Soulios C, Cox BJ, et al: Brief treatment of emergency room patients with panic attacks. *Am J Psychiatry* 149: 944, 1992.
21. American Psychiatric Association: Practice guideline for the treatment of patients with panic disorder. *Am J Psychiatry* 155: 1, 1998.
22. Bakish D, Saxena BM, Bowen R, et al: Reversible monoamine oxidase inhibitors in panic disorder. *Clin Neuropsychopharmacol* 16: S77, 1993.
23. Garcia-Borreguero D, Lauer CJ, et al: Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A. *Pharmacopsychiatry* 25: 261, 1992.
24. Woods S, Nagy LM, Koleszar AS, et al: Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. *J Clin Psychopharmacol* 12: 32, 1991.

USEFUL WEB RESOURCES

American Psychiatric Association Practice Guidelines for Treatment of Patients with Panic Disorder—http://www.psychiatryonline.com/pracGuide/pracGuideTopic_9.aspx. Accessed May 14, 2008.

Anxiety Disorders Association of America—<http://www.adaa.org>. Accessed May 14, 2008.